Oncology Equity Research Associate - Biotech Investing

LE001 Leerink Partners LLC; New York (NY); On-site; USD 110,000 - 170,000; Full time

Job summary

Leerink Partners in New York is seeking an Equity Research Associate in Oncology to join a growing team focused on cancer therapeutics. The role emphasizes public oncology biotech coverage and collaboration with physicians, scientists, and investors to inform investment ideas.

The candidate will analyze scientific data, build financial models, and monitor regulatory and competitive signals, with a strong emphasis on communicating well-supported conclusions to clients and internal stakeholders.

Qualifications

• Biotech equity research or related buy-side experience relevant to oncology.
• Experience in healthcare/life sciences or industry roles with a commercial focus.
• Familiarity with corporate/financial aspects of biotech and pharma.

Responsibilities

• Evaluate scientific, clinical, and financial factors affecting investment outcomes.
• Analyze oncology datasets (preclinical, translational, clinical).
• Build and maintain financial models and valuation frameworks.
• Support investment recommendations and research reports.
• Monitor trials, publications, patents, and regulatory updates.
• Track conferences, data presentations, and industry developments.
• Engage with physicians, management teams, and investors.
• Maintain records and follow-ups from interactions.
• Respond promptly to clinical, regulatory, and corporate developments.

Skills

Biotech equity research

Buyside experience

Healthcare consulting

Biotech industry roles

Investment banking exposure

Tools

Excel

Python

Job description

Leerink Partners in New York is seeking an Equity Research Associate in Oncology to join a growing team focused on cancer therapeutics. The role emphasizes public oncology biotech coverage and collaboration with physicians, scientists, and investors to inform investment ideas.

The candidate will analyze scientific data, build financial models, and monitor regulatory and competitive signals, with a strong emphasis on communicating well-supported conclusions to clients and internal stakeholders.